Similar to the exosome modulation technique used to formulate TRAIL-decorated EVs that showed promising anti-tumor effects when either injected at the tumor sites or in a systemic manner [68], a formulation of EVs armed with miR-15a and-miR-16 would be of useful clinical application to improve long-lasting anti-MM therapies. The gene discussed is TNFSF10; the disease is Miyoshi myopathy.